drugset / Trial / NCT05963087
Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer
Timeline
- Start
- 2023-08
- Primary completion
- 2025-02
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Dabrafenib | Small molecule | 150 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |